Table 1.

Respiratory virus infections among cohorts of asymptomatic and/or symptomatic patients with hematopoietic stem cell transplantation and/or hematologic malignancy.

Virus (References)	Study design of selected references	Laboratory methods used for viral testinga	Incidenceb (%)	Proportion of LRTIc (%)	URTI progression to LRTIc (%)	Deaths associated with LRTIc (% of LRTI)	Deaths related to overall infectiond (% total positive)
Influenza virus [5-10**, 11-14]	Prospective & retrospective	Traditional or PCR	1-4e	7-44	7-35	15-28	0-15
Respiratory syncytial virus [5, 6, 8-10**, 11, 12, 14-17]	Prospective & retrospective	Traditional or PCR	1-12	17-70	18-55	7-33	0-18
Parainfluenza [5, 6, 8-10**, 11, 14, 15, 18]	Prospective & retrospective	Traditional or PCR	0.2-18	12-50	13-43	12-50	0-14
Metapneumovirus [5, 9, 10**, 19-21*]	Prospective & retrospective	PCR	3-7	27-41	21-40	33-40	0-14
Adenovirus [5, 6, 9, 22**, 23]	Prospective	Traditional or PCR	1-19f	36-42	22-25	40-50	0-18
Rhinoviruses [5, 22**]	Prospective	Traditional or PCR	2-22		<5	NA	<5
Coronaviruses [22**]	Prospective	PCR	11	<5	<5	NA	<5
Bocavirus [24-26]	Prospective	PCR	1-3	NA	NA	NA	NA
KI polyomavirus [27*-29]	Prospective	PCR	3-22	NA	NA	NA	NA
WU polyomavirus [27*-29]	Prospective	PCR	0-7	NA	NA	NA	NA

^aTraditional laboratory methods include viral culture and direct fluorescent antibody testing

^bIncidence reported when available. In some cases, the frequency of respiratory virus infection is reported over the total observation period.

^cStudies that did not report lower respiratory tract disease cases or progression rates were not included in the results.

^dIncludes all studies, including those that did not report cases of lower respiratory tract disease.

^eMay be higher during outbreaks [5,6,12,13].

^fReflects detection in respiratory samples, and not other possible sites of disseminated adenovirus infection.

LRTI: lower respiratory tract infection; URTI: upper respiratory tract infection; NA: Not available;